Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2011-01-18
2011-01-18
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C424S085200, C424S085400, C424S093210, C424S094630, C424S094640, C424S094650, C424S094660, C424S277100, C424S530000, C424S534000, C435S174000, C530S351000
Reexamination Certificate
active
07871630
ABSTRACT:
The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1 inflammatory response in the tumor tissue, whereby the tumor tissue is diminished or destroyed and the patient develops immune memory that inhibits or prevents recurrence of the tumor.
REFERENCES:
Akbar et al., “IFN-α and IFN-β: a link between immune memory and chronic inflammation,” Immunol. Today 21(7):337-342 (2000).
Asselin-Paturel et al., “Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and RBL of non-small cell lung cancer patients,” Int. J. Cancer 77(1):7-12 (1998) (Abstract only).
Azavedo et al., “Radiological evidence of response to electrochemical treatment of breast cancer,” Clin. Radiol. 43:84-87 (1991).
Baggiolini et al., “Human Chemokines: an update,” Annu. Rev. Immunol. 15:675-705 (1997).
Bellone et al., “Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients,” Am. J. Pathol. 155(2):537-547 (1999) (Abstract only).
Bendich, “New data on vitamin C intake,” Nutrition 13(2):154-155 (1997).
Bonagura et al., “Recurrent respiratory papillomatosis: altered CD8(+)T-cell subsets and T(H)1/T(H)2 cytokine imbalance,” Clin. lmmunol. 93(3):302-311 (1999) (Abstract only).
Camp et al., “In situ cytokine production by breast cancer tumor-infiltrating lymphocytes,” Ann. Surg. Oncol. 3(2):176-184 (1996) (Abstract only).
Clive et al., “Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma,” Cancer Chemother. Pharmacol. 44 (Suppl):S29-S30 (1999).
Colantonio et al., “Upregulation of integrin α6/β1 and chemokine receptor CCR1 by Interleukin-12 promotes the migration of human type 1 helper T cells,” Blood 94(9):2981-2989 (1999).
Constant et al., “Induction of Th1 and Th2 CD4+T cell responses: The alternative approaches,” Annu. Rev. Immunol. 15:297-322 (1997).
Del Prete, “Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy,” Allergy 47(5):450-455 (1992) (Abstract only).
Del Prete, “The concept of type-1 and type-2 helper T cells and their cytokines in humans” Int. Rev. Immunol. 16(3-4):427-455 (1998) (Abstract only).
Echchakir et al., “Analysis of T-cell-receptor β-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas,” Int. J. Cancer 81:205-213 (1999).
Elsasser-Beile et al., “Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas,” Tumour Biol. 19(6):470-476 (1998) (Abstract only).
Fleischmann et al., “Systemic effects of orally administered interferons and interleukin-2,” J. Interferon Cytokine Res. 19:829-839 (1999).
Fujimoto et al., “Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state,” J. Immunol. 158(12):5619-5626 (1997) (Abstract only).
Fujisao et al., “Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma,” Br. J. Haematol. 103(2):308-310 (1998) (Abstract only).
Gallucci et al., “Danger signals: SOS to the immune system,” Curr. Op. Immunol. 13:114-119 (2001).
Ghosh et al., “Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth,” J. Natl. Cancer Inst. 87(19):1478-1483 (1995) (Abstract only).
Gingras et al., “Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue,” J. Neuroimmunol. 57(1-2):143-153 (1995) (Abstract only).
Gingras et al., “Little expression of Cytokine mRNA by fresh tumor-infiltrating mononuclear leukocytes from glioma and lung adenocarcinoma,” Cytokine 7(6):580-588 (1995).
Goedegebuure et al., “Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer,” Cellular Immunol. 175:150-156 (1997).
Gorelik et al., “Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor,” Cancer Immunol. Immunother. 39:117-126 (1994).
Gorelik et al., “Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapuetic outcome,” Cancer Immunol. Immunother. 41(6):363-374 (1995) (Abstract only).
Goto et al., “Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients,” Cancer Immunol. Immunother. 48(8):435-442 (1999) (Abstract only).
Inagawa et al., “Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necroses factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions,” Anticancer Res. 18(5D):3957-3964 (1998) (Abstract only).
Ito et al., “Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry,” Cancer Immunol. Immunother. 48(4):204-208 (1999) (Abstract only).
Jackson et al., “Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis,” J. Urol. 159(3):1054-1063 (1998) (Abstract only).
Khar et al., “High intratumoural level of cytokines mediates efficient regression of a rat histiocytoma,” Clin. Exp. Immunol. 110(1):127-131 (1977).
Kurt et al.., “T lymphocytes infiltrating sites of tumor rejection and progression display identical Vβ usage but different cytotoxic activities,” J. Immunol. 154(8):3969-3974 (1995).
Lamm, “Long-term results of intravesical therapy for superficial bladder cancer,” Urol. Clin. North Am. 19(3):573-580 (1992) (Abstract only).
Lee et al., “T helper 2-dominant antilymphoma immune response is associated with fatal outcome,” Blood 90(4):1611-1617 (1997).
Leipner et al., “Systemic enzyme therapy in oncology: effect and mode of action,” Drugs 59(4):769-780 (2000) (Abstract only).
Li et al., “Effects of direct current on dog liver: possible mechanisms for tumor electrochemical treatment,” Bioelectromagnetics 18:2-7 (1997).
Li et al., “Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells,” J. Surg. Oncol. 67:221-227 (1998).
Lowes et al., “T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas,” J. Invest. Dermatol. 108(6):914-919 (1997).
Lowin et al., “Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways,” Nature 370:650-652 (1994).
Lucey et al., “Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases,” Clin. Microbiol. Rev. 9(4):532-562 (1996) (Abstract only).
Maeurer et al., “Host immune response in renal celll cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes,” Cancer Immunol. Immunother. 41(2):111-121 (1995) (Abstract only).
Mantovani, “The chemokine system: redundancy for robust outputs,” Immunol. Today 20(6):254-257 (1999).
Matzinger, “An innate sense of danger,” Immunology 10:399-415 (1998).
Mokyr et al., “Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cur
BioTHER Corporation
Canella Karen A
LandOfFree
Therapeutic modulation of the tumor inflammatory response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic modulation of the tumor inflammatory response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic modulation of the tumor inflammatory response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727310